抗肥満薬の世界市場の評価：作用機序別、標的別、タイプ別、流通チャネル別、地域別、機会、予測（2018年～2032年）

世界の抗肥満薬の市場規模は、2024年の81億5,000万米ドルから2032年に379億5,000万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで21.21%の成長が見込まれます。市場の促進要因は、世界的な肥満率の急上昇、先進のGLP-1薬剤やマルチターゲット薬剤に対する需要の高まり、有利な規制・償還枠組みです。創薬技術やドラッグデリバリー技術の急速な革新が治療効果を高めています。さらに、北米の強力な医療インフラと政策支援が市場での優位性を強化しています。

例えば2024年12月、Rhythm Pharmaceuticals, Inc.は、米国FDAから2歳以上の患者を対象としたIMCIVREE（Setmelanotide）の承認を取得したと発表しました。この承認により、同社の製品ポートフォリオはさらに充実したものとなっています。

当レポートでは、世界の抗肥満薬市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国関税の影響

第4章 エグゼクティブサマリー

第5章 世界の抗肥満薬市場の見通し（2018年～2032年）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 作用機序別
    • 中枢作用薬
    • 末梢作用薬
  • 標的別
    • GLP-1
    • アミリン
    • グレリン
    • その他
  • タイプ別
    • 処方薬
    • OTC医薬品
  • 流通チャネル別
    • 病院薬局
    • 小売薬局・ドラッグストア
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 市場シェア分析：企業別（上位5社とその他）（金額）（2024年）
• 市場マップ分析（2024年）
  • 作用機序別
  • 標的別
  • タイプ別
  • 流通チャネル別
  • 地域別

第6章 北米の抗肥満薬市場の見通し（2018年～2032年）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 作用機序別
    • 中枢作用薬
    • 末梢作用薬
  • 標的別
    • GLP-1
    • アミリン
    • グレリン
    • その他
  • タイプ別
    • 処方薬
    • OTC医薬品
  • 流通チャネル別
    • 病院薬局
    • 小売薬局・ドラッグストア
    • オンライン薬局
  • シェア：国別
    • 米国
    • カナダ
    • メキシコ
• 各国の市場の評価
  • 米国の抗肥満薬市場の見通し（2018年～2032年）
    • 市場規模の分析と予測
    • 市場シェアの分析と予測
  • カナダ
  • メキシコ

第7章 欧州の抗肥満薬市場の見通し（2018年～2032年）

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• トルコ
• ポーランド

第8章 アジア太平洋の抗肥満薬市場の見通し（2018年～2032年）

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア
• フィリピン

第9章 南米の抗肥満薬市場の見通し（2018年～2032年）

• ブラジル
• アルゼンチン

第10章 中東・アフリカの抗肥満薬市場の見通し（2018年～2032年）

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ

第11章 需給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

• 市場促進要因
• 市場の課題

第17章 市場動向と発展

第18章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第19章 特許情勢

第20章 ケーススタディ

第21章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Eli Lilly and Company
  • Pfizer Inc.
  • Novo Nordisk A/S
  • GlaxoSmithKline PLC
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd
  • Innovent Biologics Inc.
  • Zealand Pharma A/S
  • Viking Therapeutics Inc.

第22章 戦略的提言

第23章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 3. Global Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 4. Global Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 5. Global Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 6. Global Anti-Obesity Drugs Market Share (%), By Region, 2018-2032F
• Figure 7. North America Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 8. North America Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 9. North America Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 10. North America Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 11. North America Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 12. North America Anti-Obesity Drugs Market Share (%), By Country, 2018-2032F
• Figure 13. United States Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 14. United States Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 15. United States Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 16. United States Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 17. United States Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 18. Canada Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 19. Canada Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 20. Canada Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 21. Canada Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 22. Canada Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Mexico Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Mexico Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 25. Mexico Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 26. Mexico Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 27. Mexico Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 28. Europe Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Europe Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 30. Europe Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 31. Europe Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 32. Europe Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 33. Europe Anti-Obesity Drugs Market Share (%), By Country, 2018-2032F
• Figure 34. Germany Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 35. Germany Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 36. Germany Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 37. Germany Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 38. Germany Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 39. France Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 40. France Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 41. France Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 42. France Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 43. France Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Italy Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Italy Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 46. Italy Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 47. Italy Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 48. Italy Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 49. United Kingdom Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 50. United Kingdom Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 51. United Kingdom Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 52. United Kingdom Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 53. United Kingdom Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 54. Russia Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 55. Russia Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 56. Russia Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 57. Russia Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 58. Russia Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 59. Netherlands Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 60. Netherlands Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 61. Netherlands Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 62. Netherlands Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 63. Netherlands Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. Spain Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Spain Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 66. Spain Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 67. Spain Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 68. Spain Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 69. Turkey Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Turkey Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 71. Turkey Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 72. Turkey Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 73. Turkey Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 74. Poland Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 75. Poland Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 76. Poland Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 77. Poland Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 78. Poland Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 79. South America Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 80. South America Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 81. South America Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 82. South America Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 83. South America Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 84. South America Anti-Obesity Drugs Market Share (%), By Country, 2018-2032F
• Figure 85. Brazil Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Brazil Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 87. Brazil Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 88. Brazil Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 89. Brazil Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 90. Argentina Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Argentina Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 92. Argentina Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 93. Argentina Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 94. Argentina Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 95. Asia-Pacific Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 96. Asia-Pacific Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 97. Asia-Pacific Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 98. Asia-Pacific Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 99. Asia-Pacific Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 100. Asia-Pacific Anti-Obesity Drugs Market Share (%), By Country, 2018-2032F
• Figure 101. India Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 102. India Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 103. India Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 104. India Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 105. India Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 106. China Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 107. China Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 108. China Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 109. China Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 110. China Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 111. Japan Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 112. Japan Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 113. Japan Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 114. Japan Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 115. Japan Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 116. Australia Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 117. Australia Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 118. Australia Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 119. Australia Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 120. Australia Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 121. Vietnam Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 122. Vietnam Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 123. Vietnam Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 124. Vietnam Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 125. Vietnam Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 126. South Korea Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 127. South Korea Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 128. South Korea Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 129. South Korea Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 130. South Korea Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. Indonesia Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 132. Indonesia Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 133. Indonesia Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 134. Indonesia Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 135. Indonesia Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 136. Philippines Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 137. Philippines Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 138. Philippines Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 139. Philippines Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 140. Philippines Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 141. Middle East & Africa Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 142. Middle East & Africa Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 143. Middle East & Africa Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 144. Middle East & Africa Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 145. Middle East & Africa Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 146. Middle East & Africa Anti-Obesity Drugs Market Share (%), By Country, 2018-2032F
• Figure 147. Saudi Arabia Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 148. Saudi Arabia Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 149. Saudi Arabia Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 150. Saudi Arabia Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 151. Saudi Arabia Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 152. UAE Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 153. UAE Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 154. UAE Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 155. UAE Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 156. UAE Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 157. South Africa Anti-Obesity Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 158. South Africa Anti-Obesity Drugs Market Share (%), By Mechanism of Action, 2018-2032F
• Figure 159. South Africa Anti-Obesity Drugs Market Share (%), By Target, 2018-2032F
• Figure 160. South Africa Anti-Obesity Drugs Market Share (%), By Type, 2018-2032F
• Figure 161. South Africa Anti-Obesity Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 162. By Mechanism of Action Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 163. By Target Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 164. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global anti-obesity drugs market is projected to witness a CAGR of 21.21% during the forecast period 2025-2032, growing from USD 8.15 billion in 2024 to USD 37.95 billion in 2032. The market is being driven by the global surge in obesity rates, rising demand for advanced GLP-1 and multi-target drugs, and favorable regulatory and reimbursement frameworks. Rapid innovations in drug discovery and delivery technologies are enhancing treatment efficacy. Additionally, North America's strong healthcare infrastructure and policy support are reinforcing market dominance.

For instance, in December 2024, Rhythm Pharmaceuticals, Inc. announced that the United States FDA had granted approval for IMCIVREE (Setmelanotide) for patients aged 2 years and older, aimed at reducing excess body weight and sustaining long-term weight reduction. This approval has enhanced the company's product portfolio.

Increasing Global Obesity Prevalence and Related Comorbidities

The global anti-obesity drugs market is experiencing strong growth driven by an alarming rise in obesity prevalence worldwide. Obesity is increasingly being recognized as a major health crisis due to its association with life-threatening comorbidities such as cardiovascular diseases, type 2 diabetes, and certain cancers. Sedentary lifestyles, unhealthy diets, and urbanization significantly contribute to this trend. As awareness about the long-term impacts of obesity increases, there is a growing shift toward pharmacological solutions when lifestyle interventions fail. The surge in obesity-related healthcare costs is prompting governments and insurers to support weight loss therapies. This dynamic creates a favorable environment for adopting effective anti-obesity medications. For instance, according to the World Obesity Atlas 2023, over 4 billion people-more than half of the global population-will be overweight or obese by 2035, with related healthcare costs projected to exceed USD 4 trillion annually.

Strong Pipeline and Technological Innovation Fuels Market Growth

The robust pipeline of anti-obesity drugs and recent technological breakthroughs in drug formulation, delivery systems, and molecular targeting are significantly propelling the global market growth. Companies are shifting focus from traditional appetite suppressants to next-generation molecules with higher efficacy and fewer side effects. Biotech firms and pharma giants are leveraging AI and machine learning to accelerate obesity drug discovery and enhance precision targeting. Additionally, collaborations and licensing agreements are expediting the commercialization of innovative therapeutics. These efforts are expanding treatment options and improving patient adherence and outcomes. For instance, in November 2023, the U.S. Food and Drug Administration approved Eli Lilly and Company's Zepbound (tirzepatide) injection, marking it as the first activator of GIP and GLP-1 hormone receptors for obesity, based on the results of phase 3 trials, which indicate considerable weight loss potential accompanied by gastrointestinal side effects.

Rapid Advancements in GLP-1 and Multi-Target Therapeutics

Segment-specific innovation is accelerating the expansion of the anti-obesity drugs market, particularly through the development of glucagon-like peptide-1 (GLP-1) receptor agonists. These therapies promote weight loss by enhancing satiety and reducing appetite but also offer metabolic benefits, including better glycemic control. Pharmaceutical companies are now exploring multi-target drugs that combine GLP-1, amylin, or GIP actions to maximize therapeutic effect. As new drug candidates demonstrate superior efficacy in clinical trials compared to older therapies, interest in this mechanism of action continues to rise. This is resulting in an influx of investments in clinical R&D, pipeline expansion, and faster regulatory pathways for novel drugs.

For instance, in December 2024, Novo Nordisk A/S announced promising Phase 3 results for its once-weekly amylin-GLP-1 dual agonist "CagriSema," showing greater weight loss in patients compared to semaglutide alone.

North America Maintains Market Leadership

Regionally, North America holds the largest share in the global anti-obesity drugs market, driven by high obesity prevalence, established healthcare infrastructure, and rapid adoption of new therapies. The United States, in particular, leads in both consumption and development of anti-obesity drugs, thanks to strong reimbursement policies, frequent regulatory approvals, and a large, health-conscious population. Moreover, rising pressure from employers and insurers to combat obesity-related productivity losses is driving broader coverage for pharmacologic treatments. Market growth is also supported by increased DTC (Direct-to-Consumer) advertising and telemedicine platforms facilitating easier access to prescriptions. In November 2023, the U.S. FDA approved Zepbound (tirzepatide) by Eli Lilly for chronic weight management in adults with obesity or overweight and comorbid conditions, boosting its accessibility across U.S. pharmacies.

Future Market Scenario (2025-2032F)

The global anti-obesity drugs market is expected to witness exponential growth in the coming years, fueled by the surging global obesity rates and increasing demand for effective weight management solutions. With technological advancements in drug development, especially in GLP-1 receptor agonists and multi-target drugs, the market is shifting toward more personalized and potent therapeutic options. Rising healthcare expenditure, increased awareness of obesity-related comorbidities, and improved reimbursement scenarios are further accelerating adoption. In addition, expansion into emerging markets, growing telemedicine adoption, and supportive regulatory initiatives are creating new opportunities for drug manufacturers. The market is also poised for consolidation, with major players investing heavily in clinical trials and strategic partnerships to dominate this evolving space.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of anti-obesity drugs and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, in January 2024, F. Hoffmann-La Roche Ltd completed the acquisition of Carmot Therapeutics for USD 2.7 billion, along with an additional USD 400 million contingent on milestones, thereby obtaining rights to clinical-stage obesity treatments, notably the primary asset CT-388, which targets obesity and related conditions.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Anti-Obesity Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Mechanism of Action
    • 5.2.1.1. Centrally Acting Drugs
    • 5.2.1.2. Peripheral Acting Drugs
  • 5.2.2. By Target
    • 5.2.2.1. GLP-1
    • 5.2.2.2. Amylin
    • 5.2.2.3. Ghrelin
    • 5.2.2.4. Others
  • 5.2.3. By Type
    • 5.2.3.1. Prescription Drugs
    • 5.2.3.2. OTC Drugs
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Retail Pharmacies and Drug Stores
    • 5.2.4.3. Online Pharmacies
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Mechanism of Action
  • 5.3.2. By Target
  • 5.3.3. By Type
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Anti-Obesity Drugs Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Mechanism of Action
    • 6.2.1.1. Centrally Acting Drugs
    • 6.2.1.2. Peripheral Acting Drugs
  • 6.2.2. By Target
    • 6.2.2.1. GLP-1
    • 6.2.2.2. Amylin
    • 6.2.2.3. Ghrelin
    • 6.2.2.4. Others
  • 6.2.3. By Type
    • 6.2.3.1. Prescription Drugs
    • 6.2.3.2. OTC Drugs
  • 6.2.4. By Distribution Channel
    • 6.2.4.1. Hospital Pharmacies
    • 6.2.4.2. Retail Pharmacies and Drug Stores
    • 6.2.4.3. Online Pharmacies
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Anti-Obesity Drugs Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Mechanism of Action
        • 6.3.1.2.1.1. Centrally Acting Drugs
        • 6.3.1.2.1.2. Peripheral Acting Drugs
      • 6.3.1.2.2. By Target
        • 6.3.1.2.2.1. GLP-1
        • 6.3.1.2.2.2. Amylin
        • 6.3.1.2.2.3. Ghrelin
        • 6.3.1.2.2.4. Others
      • 6.3.1.2.3. By Type
        • 6.3.1.2.3.1. Prescription Drugs
        • 6.3.1.2.3.2. OTC Drugs
      • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.4.1. Hospital Pharmacies
        • 6.3.1.2.4.2. Retail Pharmacies and Drug Stores
        • 6.3.1.2.4.3. Online Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Anti-Obesity Drugs Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Anti-Obesity Drugs Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Anti-Obesity Drugs Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Anti-Obesity Drugs Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Regulatory Approvals
• 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Eli Lilly and Company
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. Pfizer Inc.
  • 21.3.3. Novo Nordisk A/S
  • 21.3.4. GlaxoSmithKline PLC
  • 21.3.5. Boehringer Ingelheim International GmbH
  • 21.3.6. AstraZeneca plc
  • 21.3.7. F. Hoffmann-La Roche Ltd
  • 21.3.8. Innovent Biologics Inc.
  • 21.3.9. Zealand Pharma A/S
  • 21.3.10. Viking Therapeutics Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer